Treatment of Advanced Coats' Disease With Combination Therapy of Laser Photocoagulation, Intravitreal Ranibizumab, and Sub-Tenon Methylprednisolone Acetate.

PURPOSE To investigate the efficacy of combination therapy with laser photocoagulation, intravitreal ranibizumab, and sub-Tenon methylprednisolone acetate in patients presenting with advanced Coats' disease. METHODS This was a retrospective analysis of 16 patients who underwent laser photocoagulation combined with intravitreal ranibizumab and sub-Tenon methylprednisolone acetate between 2008 and 2017. The primary outcome was anatomic success and the secondary outcomes were globe preservation and final visual acuity. RESULTS The average age at surgery was 5.12 ± 2.7 years (range: 3 to 10 years). The mean follow-up time was 45.43 ± 29.01 months (range: 12 to 108 months). Of the 16 patients (16 eyes) reviewed, 6 patients had stage 3A and 10 patients had stage 3B Coats' disease. The mean number of applications was 10 (range: 4 to 18). Globe preservation was achieved in all patients. Final visual acuity outcomes were satisfactory: 20/20 to 20/50 in 2 patients, 20/60 to 20/100 in 1 patient, and 20/200 or worse in 13 patients. CONCLUSIONS Intravitreal ranibizumab used in combination with laser photocoagulation and sub-Tenon methylprednisolone acetate could be an effective treatment option for patients with advanced Coats' disease. The combined therapy achieved anatomical success, globe preservation, and reasonable visual acuity outcomes. [J Pediatr Ophthalmol Strabismus. 20XX;XX(X):XX-XX.].

[1]  Xiaorong Li,et al.  The efficacy of conbercept or ranibizumab intravitreal injection combined with laser therapy for Coats’ disease , 2018, Graefe's Archive for Clinical and Experimental Ophthalmology.

[2]  M. Trese,et al.  Long-Term Outcomes of Total Exudative Retinal Detachments in Stage 3B Coats Disease. , 2018, Ophthalmology.

[3]  Song-Feng Li,et al.  The effects of a treatment combination of anti-VEGF injections, laser coagulation and cryotherapy on patients with type 3 Coat’s disease , 2017, BMC Ophthalmology.

[4]  W. Wei,et al.  Successful use of intravitreal ranibizumab injection and combined treatment in the management of Coats' disease , 2016, Acta ophthalmologica.

[5]  A. Berrocal,et al.  Treatment of Coats' Disease With Combination Therapy of Intravitreal Bevacizumab, Laser Photocoagulation, and Sub-Tenon Corticosteroids. , 2016, Ophthalmic surgery, lasers & imaging retina.

[6]  Peiquan Zhao,et al.  Treatment of stage 3 Coats’ disease by endolaser photocoagulation via a two-port pars plana nonvitrectomy approach , 2015, Graefe's Archive for Clinical and Experimental Ophthalmology.

[7]  K. Sugioka,et al.  Combined treatment for Coats’ disease: retinal laser photocoagulation combined with intravitreal bevacizumab injection was effective in two cases , 2014, BMC Ophthalmology.

[8]  A. Yaman,et al.  Intravitreal Dexamethasone Implant (Ozurdex) in Coats’ Disease , 2013, Case Reports in Ophthalmology.

[9]  S. Kase,et al.  Expression of vascular endothelial growth factor in eyes with Coats' disease. , 2013, Investigative ophthalmology & visual science.

[10]  D. Barañano,et al.  Treatment of Coats’ disease with intravitreal bevacizumab , 2012, British Journal of Ophthalmology.

[11]  Han-guo Zhang,et al.  Increased nitric oxide and vascular endothelial growth factor levels in the aqueous humor of patients with coats' disease. , 2012, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[12]  I. Chatziralli,et al.  Diagnosis and Treatment of Coats’ Disease: A Review of the Literature , 2012, Ophthalmologica.

[13]  C. Shields,et al.  Bevacizumab for Coats' disease with exudative retinal detachment and risk of vitreoretinal traction , 2011, British Journal of Ophthalmology.

[14]  B. Ghosh,et al.  Role of intravitreal bevacizumab in adult onset Coats’ disease , 2011, International Ophthalmology.

[15]  K. Park,et al.  Combined Photodynamic Therapy and Intravitreal Bevacizumab Injection for the Treatment of Adult Coats' Disease: A Case Report , 2010, Korean journal of ophthalmology : KJO.

[16]  B. Foot,et al.  A population-based study of Coats disease in the United Kingdom I: epidemiology and clinical features at diagnosis , 2010, Eye.

[17]  Hao Wang,et al.  Elevated vascular endothelial growth factor level in Coats’ disease and possible therapeutic role of bevacizumab , 2010, Graefe's Archive for Clinical and Experimental Ophthalmology.

[18]  I. Othman,et al.  Management of lipid exudates in Coats disease by adjuvant intravitreal triamcinolone: effects and complications , 2009, British Journal of Ophthalmology.

[19]  S. Dimitrakos,et al.  Coats’ disease: treatment with intravitreal bevacizumab and laser photocoagulation , 2009, Acta ophthalmologica.

[20]  Atul K. Jain,et al.  Elevated vascular endothelial growth factor levels in Coats disease: rapid response to pegaptanib sodium , 2007, Graefe's Archive for Clinical and Experimental Ophthalmology.

[21]  A. Javadzadeh.  The effect of posterior subtenon methylprednisolone acetate in the refractory diabetic macular edema: a prospective nonrandomized interventional case series , 2006, BMC ophthalmology.

[22]  Y. Guex-Crosier,et al.  Posterior sub-Tenon’s steroid injections for the treatment of posterior ocular inflammation: indications, efficacy and side effects , 1999, Graefe's Archive for Clinical and Experimental Ophthalmology.

[23]  W. Tasman,et al.  Natural history and management of advanced Coats' disease. , 1988, Ophthalmic surgery.